SciBase Holding AB (”SciBase” or the “Company”) has updated the Company’s financial calendar for 2021.
As the previous published date for the interim report for the first quarter, May 13th, is a national holiday, the date has now been changed to May 12th.
The updated financial calendar is set out as follows:
May 12 Interim report Q1 2021
May 18 Annual general meeting 2021
August 19 Interim report Q2 2021
November 11 Interim report Q3 2021
For more information, please contact: Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: [email protected]
About SciBase and Nevisense SciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.
SciBase hereby announces that the Annual report for 2020 is available at the Company's website www.scibase.com.
A pdf-version of the annual report is enclosed to this press-release.A printed version of the Annual report will only be distributed to shareholders who actively request a printed copy. For more information, please contact:
The information was submitted for publication, through the agency of the contact person set out above, at 09.00 CET on April 9, 2021.
About SciBase and Nevisense
SciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.
STOCKHOLM, SWEDEN, - April 12, 2021 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today the publication of a new clinical study supporting SciBase's strategy to develop multiple clinical applications for the Nevisense and Nevisense Go platforms.
The study is from the Swiss institute of Allergy and Asthma Research (SIAF) and has been published in the European Journal of Allergy and Clinical Immunology (Allergy). In the study Nevisense was used to assess the skin barrier of patients with atopic dermatitis (AD) and could accurately detect signs of atopic dermatitis even on unaffected skin. The Nevisense measurement also correlated with relevant biomarkers for atopic dermatitis.
SIAF, based in Davos, is a world leader within applied allergy and asthma research. SIAF is headed by Director Cezmi Akdis, who is also Professor of the University of Zurich Medical Faculty and one of the directors of the Christine Kühne Center for Allergy Research and Education.
Professor Akdis said `Personalized and precision medicine is becoming one of the most exciting areas in all of medicine. Our research group has proposed the "epithelial barrier hypothesis", which asserts that defective epithelial skin barriers are the main reason for the initiation and increase of allergic and autoimmune conditions such as asthma, atopic dermatitis and inflammatory bowel disease. Furthermore, leakiness of the gut epithelium is also implicated in conditions such as diabetes, obesity, multiple sclerosis, rheumatoid arthritis and others. Moreover, distant microinflammatory responses due to a `leaky gut' and microbiome changes are suspected in Alzheimer's disease, Parkinson's disease, chronic depression and autism spectrum disorders.
Defective skin barrier is an important part of the "epithelial barrier hypothesis". Atopic dermatitis alone affects more than 10% of infants, and represents a huge health and socioeconomic burden. Skin barrier assessment shows potential to be clinically useful for early prediction of disease development, improved diagnosis, disease follow-up and therapy evaluation.
This study shows that the Nevisense method can directly assess the status of epithelial barrier using electrical impedance spectroscopy (EIS). EIS was able to assess epithelial skin barrier integrity, differentiate between patients and controls without AD and characterize lesional and non-lesional skin of patients. EIS also showed a significant correlation with biomarkers associated with inflammatory pathways that may affect the skin barrier. Furthermore, copy numbers of filaggrin, an essential skin barrier molecule significantly correlated with EIS on non-lesional skin of patients. These findings that are presented in the article strongly indicates that Nevisense and the EIS method is a useful tool to detect skin barrier dysfunction.'
SciBase CEO Simon Grant commented "This is an exciting new application area for SciBase, and one where we have unique advantages. Barrier-related diseases are widespread, and assessment of the barrier can help better understand and treat patients. The study illustrates the potential for Nevisense to become a valuable tool for clinicians within AD and other epithelial barrier-related diseases. We see a number of applications with broad market potential, and we are working with SIAF and others to develop clinical products. For SciBase this an important milestone in our strategy to develop multiple clinical applications using our unique technology platform."
The study can be found here : https://onlinelibrary.wiley.com/doi/10.1111/all.14842?af=R.
For more information please contact: Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: [email protected]
About SciBase and Nevisense SciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.
About SIAF-SFI
The Swiss Institute of Allergy and Asthma Research (SIAF) is a department of the foundation Swiss Research Institutes for High Altitude Climate and Medicine Davos (SFI), an affiliated institute of the University of Zurich, and member of the Life Science Zurich Graduate School. SIAF members play leading roles in national and international organizations, such as European Academy of Allergy and Clinical Immunology and in editorial boards and editorships of top Journals in the field of allergy asthma and clinical immunology. At the same time, SIAF fulfills teaching obligations in the University of Zurich. The research activities at SIAF are focused on patient-relevant translational research and the investigation of the immunological principles in the field of skin atopic dermatitis, allergies and asthma to develop approaches for new preventive and curative treatments for patients. SIAF also promotes personalized medicine to develop treatment approaches that are better tailored to the needs of individual patients. These personalized medicine research activities are expected to not only help to find tailor-made therapies but also to develop more precise diagnosis. The continuously growing SIAF is one of the most cited and leading institutes in its area worldwide with more than 50,000 citations and 1,000 original research articles in the last 20 years. SIAF organizes the internationally renowned World Immune Regulation Meeting (WIRM) in Davos every year. SIAF works in close collaboration with the Christine Kühne-Center for Allergy Research and Education (CK-CARE), Davos. Further information is available at www.siaf.uzh.ch.
STOCKHOLM, SWEDEN, - April 12, 2021 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that it has today received information that the certification process under the new Medical Device Regulation (MDR 2017/745) has been slightly delayed due to resource issues at the notified body.
As there are no outstanding questions, we expect that the internal process at the notified body will be finalized by the end of April thus delaying the certification process by two weeks from our expected date.
MDR is a set of mandatory legal requirements and central for all companies selling medical devices in the EU. The new regulation will come into force on the 26th of May this year.
"Unfortunately, Covid-19 and the extremely high pressure on all notified bodies from Companies has delayed our MDR certification by two weeks. This is both unexpected and highly frustrating after more than two years working on this project, but this part of the process is out of our hands. At this time we do not see a risk for further delay, but this final step lies with our notified body." says Simon Grant, CEO of SciBase.
For more information please contact: Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: [email protected]
About SciBase and Nevisense SciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.
The loss after tax amounted to TSEK 9,839 (10,207).
The loss per share amounted to SEK 0.20 (0.61).
The cash flow from current operations was negative in the amount of TSEK 10,290 (8,842).
The gross margin reached 49.4% (58.0%).
Electrode sales volume increased by 4% and reached 7,492 (7,180) units. Repeat sales of electrodes to existing customers increased by 6%.
The full year in figures
Net sales amounted to TSEK 9,521 (9,276).
The loss after tax amounted to TSEK 34,989 (39,594).
The loss per share amounted to SEK 1.12 (2.38).
The cash flow from current operations was negative in the amount of TSEK 33,861 (37,956).
The gross margin reached 52.5% (54.5%).
Electrode sales volume increased by 8% and reached 25,686 (23,724) units. Repeat sales of electrodes to existing customers increased by 9%.
Important events during the quarter
The negative impact of Covid-19 seen in the first half of the year lessened in Q3 and in Q4 sales reached a new quarterly high. Sales in the company's key market Germany increased by 15% while overall sales increased by 9%. The market situation however remains difficult to predict going forward, due to ongoing lockdowns and reduced marketing activities.
SciBase announced the outcome of the exercise of warrants of series TO1. In total 91.4% of the warrants were subscribed for at a price of SEK 1.75, raising MSEK 30 net.
Nevisense Go, SciBase's next generation handheld platform, was released at the end of October. The first version of Nevisense Go will be used by researchers and industrial partners to assess skin barrier function.
SciBase was granted a Category III CPT® code for the Nevisense melanoma detection test in the US.
Two US studies showing improved detection of melanoma by clinicians with Nevisense were published in leading US journals. The studies compared the evaluation of atypical, pigmented skin lesions using visual evaluation alone to visual evaluation plus Nevisense.
The first study validating the use of Nevisense in Non-melanoma skin cancer was published.
Nevisense was included in infant study at Mount Sinai Hospital in New York. Nevisense will be used to measure skin properties including barrier function and evaluate whether these measurements can help predict the development of allergies or monitor their progress.
Linn Olsen, SciBase's head of production and supply chain, has been appointed as a member of the management team.
Important events after the end of the period
A further German study evaluating the value of using Nevisense on suspected Non-melanoma skin cancer (NMSC, also known as Keratinocyte cancer) in normal clinical practice was published.
A nominating committee was appointed.
July 1 - Sep 30
Jan 1 - Sep 30
THE GROUP
2020
2019
2020
2019
Net sales, SEK ths
3 055
2 800
9 521
9 276
Gross margin, %
49,4%
58,0%
52,5%
54,5%
Equity/Asset ratio, %
79,1%
69,4%
79,1%
69,4%
Net indebtness, multiple
0,26
0,44
0,26
0,44
Cash equivalents, SEK ths
41 427
26 456
41 427
26 456
Cashflow from operating activities, SEK ths
-10 290
-8 842
-33 861
-37 956
Earnings per share (before and after dilution), SEK
-0,20
-0,61
-1,12
-2,38
Shareholder's equity per share, SEK
0,96
1,93
1,50
1,93
Average number of shares, 000'
48 707
16 618
31 287
16 618
Number of shares at closing of period, 000'
54 780
16 618
54 780
16 618
Share price at end of period, SEK
4,62
4,36
4,62
4,36
Number of sold electrodes, pieces
7 492
7 180
25 686
23 724
Average number of employees
17
18
16
18
This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on February 19, 2021.Contact person: Michael Colérus, CFO. +46 70 341 34 72
For more information, please contact:
Simon Grant, CEO SciBase
Phone: +46 72 887 43 99
Email: [email protected]
About SciBase and Nevisense SciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.
A new study published in the Journal of the American Academy of Dermatology (JAAD) shows that COVID-19 has materially delayed diagnosis for patients with skin cancer and a substantial backlog of undiagnosed cases remain. Rates of skin cancer detection in the study were down by 43-51%. These delays in initial diagnosis and treatment may lead to skin cancers presenting at more advanced stages, with potential increased morbidity and worse melanoma survival outcomes.
The study was based on data collected by the Advanced Dermatology and Cosmetic Surgery (ADCS) group of practices in the US. ADCS is a key partner for SciBase in the US, though SciBase was not directly involved in the study.
"This study shows that COVID-19 has had a significant negative effect on the rates of skin cancer diagnosis, primarily due to a reluctance from patients to visit clinics. This effect has been seen in Europe as well. We expect an increased focus on skin cancer and diagnosis once effects of the pandemic have subsided, and this represents a likely increase in demand for products such as ours", says Simon Grant, CEO of SciBase.
The article can be accessed through the following link: https://www.jaad.org/article/S0190-9622%2821%2900082-7/fulltext
For more information please contact: Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: [email protected]
About SciBase and Nevisense SciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.
SciBase's head of product development, David Melin, has resigned from his position and has accepted a role at another company. The company is reviewing options for the role going forward.
"I would like to take the opportunity to thank David for his exceptional work at SciBase, and especially his work with our Nevisense hardware platforms. David has managed a very well-functioning development team, and I wish him all the best in his future role", says Simon Grant CEO SciBase.
For more information, please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: [email protected]
The information was submitted, through the agency of the contact person set out above, for publication at the time stated by SciBase's news distributor Cision upon publication of this press release.
About SciBase and Nevisense SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed and sells a unique point-of-care device for evaluation of skin disorders such as skin cancer and atopic dermatitis. Its first product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and inflammation. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies and abnormalities. SciBase is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.
New clinical study supports expansion of indications for Nevisense
Study performed in Germany validates the use of Nevisense in non-melanoma skin cancer
The study publication is an important milestone in the plan to broaden the areas of use of Nevisense
A new study supporting the use of Nevisense for the evaluation of lesions where there is a suspicion of non-melanoma skin cancer (NMSC) has been published in "Acta Dermato-Venereologica". The article is authored by Dr Esra Sarac, Prof Claus Garbe and others from Eberhard Karls University in Tübingen, Germany. NMSC represents a new indication that complements the current melanoma indication and greatly expands the utility of Nevisense for clinicians working with skin cancer.
"This study shows that Nevisense is a valuable tool not only for melanoma but also for other types of skin cancer such as basal cell carcinoma and squamous cell carcinoma. These non-melanoma skin cancers are 10-15 times more prevalent than melanoma, and so the new indication will be more useful to more clinicians and patients. The publication is another milestone in our strategy to broaden the clinical applications and markets for Nevisense. Nevisense with NMSC is now in the final stages of regulatory approval in the EU as part of the new Medical Device Regulation approval route. Once approved, we expect the added indication will make Nevisense more attractive for new customers and expand the level of usage of existing customers", says Simon Grant, CEO of SciBase.
The article is titled "Diagnostic Accuracy of Electrical Impedance Spectroscopy in Nonmelanoma Skin Cancer" and evaluates the accuracy of Nevisense and Electrical Impedance spectroscopy (EIS) on suspected non-melanoma skin cancers. The article shows that Nevisense is well suited for use with NMSC and states that "EIS has good discriminative power to distinguish NMSC from benign cutaneous lesions". The conclusion in the article states: "The results of this study suggest that electrical impedance spectroscopy measurements can improve diagnostic performance with a high sensitivity in detection of non-melanoma skin cancer."
The article is now available in online form at the Acta Dermato-Venereologica's website (https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-3689) and will be distributed in print in the next issue of the publication.
For more information please contact: Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: [email protected]
About SciBase and Nevisense SciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.
The appointments have been made in accordance with the instructions regarding principles for the appointment of the company nominating committee which were determined at the Annual General Meeting of SciBase Holding on June 17, 2020. Note, however, that the appointment took into account changes in ownership that took place during the end of 2020.
The Annual General Meeting of SciBase Holding AB (publ) will be held on May 18, 2021 in Stockholm.
Shareholders who wish to have an item considered at the Annual General Meeting can submit a request to the Board to this effect. Such a request for an item to be considered is to be sent to SciBase Holding AB (publ), Att: Chairman of the Board, Box 3337, 103 67 Stockholm, and must have been received by the Board no later than seven weeks before the Annual General Meeting, or otherwise in such good time that the matter, where necessary, can be included in the notice to attend the Annual General Meeting.
Stockholm, February 2, 2021
SciBase Holding AB (publ)
For more information, please contact: Tord Lendau, Chairmain of the board, phone +46 (0)70 810 01 67
About SciBase and Nevisense SciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.
A new clinical study from Germany including nearly 1,000 patients confirms the value of Nevisense when used to evaluate suspected Non-melanoma skin cancer (NMSC)
The study publication is an important milestone in SciBase's strategy to broaden the areas of use and potential markets for Nevisense
A new clinical study evaluating the value of using Nevisense on suspected Non-melanoma skin cancer (also known as Keratinocyte cancer) in normal clinical practice is now published. The article named "Retrospective evaluation of the performance of the electrical impedance spectroscopy system Nevisense in detecting keratinocyte cancer" reviewed clinical results when Nevisense was used on lesions with a suspicion of skin cancer.
The study included a total of 1,712 lesions and 951 patients, collected at a private clinic in Germany over a period of 4 years. The study confirmed the ability of Nevisense to accurately identify non-melanoma skin cancers with a sensitivity of 98,4%. In addition, the study showed that when using Nevisense almost half of the lesions examined did not require a biopsy. The article concludes that Nevisense is a valuable adjunct support tool in clinical decisions for cases with suspicion of non-melanoma skin cancer. The article is available through the following link: http://dx.doi.org/10.1111/srt.13007
These results support a new clinical application that is an important part of our growth strategy. We continue to leverage our technology platform to both add clinical value and expand the market segments we address. We believe that the Non-melanoma Skin Cancer application will help us achieve both goals, and short term be key in accelerating our growth in Germany. We look forward to releasing the application as soon as our Medical Device Regulation approval is complete, which we expect around the end of the first quarter", says Simon Grant, CEO of SciBase.
For more information please contact: Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: [email protected]
About SciBase and Nevisense SciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.
